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Abstract
Background: A hallmark of the prion diseases is the conversion of the host-encoded cellular prion protein (PrP
C) into a
disease related, alternatively folded isoform (PrP
Sc). The accumulation of PrP
Sc within the brain is associated with synapse
loss and ultimately neuronal death. Novel therapeutics are desperately required to treat neurodegenerative diseases
including the prion diseases.
Principal Findings: Treatment with glimepiride, a sulphonylurea approved for the treatment of diabetes mellitus, induced
the release of PrP
C from the surface of prion-infected neuronal cells. The cell surface is a site where PrP
C molecules may be
converted to PrP
Sc and glimepiride treatment reduced PrP
Sc formation in three prion infected neuronal cell lines (ScN2a,
SMB and ScGT1 cells). Glimepiride also protected cortical and hippocampal neurones against the toxic effects of the prion-
derived peptide PrP82–146. Glimepiride treatment significantly reduce both the amount of PrP82–146 that bound to
neurones and PrP82–146 induced activation of cytoplasmic phospholipase A2 (cPLA2) and the production of prostaglandin
E2 that is associated with neuronal injury in prion diseases. Our results are consistent with reports that glimepiride activates
an endogenous glycosylphosphatidylinositol (GPI)-phospholipase C which reduced PrP
C expression at the surface of
neuronal cells. The effects of glimepiride were reproduced by treatment of cells with phosphatidylinositol-phospholipase C
(PI-PLC) and were reversed by co-incubation with p-chloromercuriphenylsulphonate, an inhibitor of endogenous GPI-PLC.
Conclusions: Collectively, these results indicate that glimepiride may be a novel treatment to reduce PrP
Sc formation and
neuronal damage in prion diseases.
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Introduction
The transmissible spongiform encephalopathies, otherwise
known as prion diseases include Creutzfeldt-Jakob disease and
kuru in humans, as well as important livestock diseases such as
scrapie in sheep and goats and bovine spongiform encephalopathy
in cattle. The central event in these diseases is the conversion of a
host encoded cellular prion protein (PrP
C) into abnormally folded,
disease-associated isoforms (PrP
Sc) in the brains of infected animals
[1]. Although the primary amino acid sequence remains the same,
during the conversion process a portion of the a-helix and random
coil structure in PrP
C is refolded into a b-pleated sheet in PrP
Sc
[2]. This change in secondary structure is accompanied by
changes in the biological and biochemical properties of the PrP
Sc
protein, including reduced solubility and an increased resistance to
proteases [3]. Consequently, aggregates of PrP
Sc accumulate in
association with neurones in affected brain areas [4], a process
which is thought to lead to synapse degeneration and ultimately
neuronal death. PrP
Sc is believed to constitute the major and
perhaps only component of the infectious particle [5]. While the
correlation between PrP
Sc and infectivity is not completely clear
[6], cell based studies routinely measure the amount of PrP
Sc as an
indicator of infectivity.
The production of PrP
Sc and the progression of prion diseases
are dependent upon the presence of PrP
C [7,8,9]. PrP
C is linked to
the membrane by a glycosylphosphatidylinositol (GPI) anchor [10]
and can be released from the surface of cells by treatment with
phosphatidylinositol-phospholipase C (PI-PLC) [11]. Treatment of
prion-infected neuronal cells with PI-PLC reduced PrP
Sc forma-
tion [12,13] indicating that PrP
Sc is formed from PrP
C expressed
at the cell surface, or from PrP
C that had been expressed at the cell
surface. This conclusion is supported by observations that PrP
C
reactive antibodies reduced PrP
Sc formation in prion-infected
neuronal cells [14,15]. Thus, any treatment that affected the
amount of PrP
C expressed at the cell surface may also be expected
to affect PrP
Sc formation.
Glimepiride is a sulphonylurea used to treat non insulin-
dependent diabetes mellitus. It some cells it activates an
endogenous GPI-PLC [16,17]. Thus, in adipocytes glimepiride
treatment released some GPI-anchored proteins from surface
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anchored proteins [20]. We therefore investigated the effect of
glimepiride treatment on the amount of PrP
C at the surface of
primary cortical neurones and prion-infected neuronal cell lines.
Glimepiride treatment reduced the amount of PrP
C at the surface
of neuronal cell lines and primary cortical neurones. The effects of
glimepiride were similar to the effects of PI-PLC; both caused the
release of a soluble, deacylated PrP
C. Treatment with glimepiride
also reduced PrP
Sc formation in 3 prion-infected neuronal cell
lines (ScGT1, SMB and ScN2a cells). In addition, the effects of
glimepiride treatment on prion neurotoxicity were examined.
PrP
C is required for the neurotoxicity of PrP
Sc [21] and the process
of prion-induced neurodegeneration is commonly examined by
incubating neurones with either recombinant PrP or specific PrP-
derived peptides. A synthetic peptide containing amino acids 82 to
146 of the human PrP protein (PrP82–146) corresponding to a
major PrP fragment isolated from the brains of patients with
Gerstmann-Stra ¨ussler-Scheinker disease (GSS) [22], was toxic to
cultured cortical neurones [23,24]. Here we report the effects of
glimepiride on PrP82–146 induced activation of cytoplasmic
phospholipase A2 (cPLA2) and neuronal survival.
Methods
Cell lines
Prion-infected neuronal cell lines (ScGT1, ScN2a and SMB
cells) [25,26,27] were grown in Ham’s F12 medium supplemented
with 2 mM glutamine, 2% foetal calf serum (FCS) and standard
antibiotics (100 U/ml penicillin and 100 mg/ml streptomycin).
Cells were plated in 6 well plates (10
5 cells/well) and allowed to
adhere overnight before the addition of test compounds. The
medium was changed twice daily and the amount of cell-
associated PrP
Sc measured after 7 days. Cells were washed twice
in phosphate buffered saline (PBS) and homogenised at 10
6 cells/
ml in an extraction buffer containing 10 mM Tris-HCl, 100 mM
NaCl, 10 mM EDTA, 0.5% Nonidet P-40 and 0.5% sodium
deoxycholate. Nuclei and large fragments were removed by
centrifugation (3006g for 5 minutes) and the supernatant digested
with 5 mg/ml proteinase K for 1 hour at 37uC, digestion was
stopped using mixed protease inhibitors (AEBSF, Aprotinin,
Leupeptin, Bestain, Pepstatin A and E-46) (Sigma, Poole, UK).
Culture supernatants were also collected to see if PrP
Sc was
released from cells. They were digested with 5 mg/ml proteinase K
for 1 hour at 37uC and stopped with mixed protease inhibitors (as
above). In some studies cell extracts/supernatants were digested
with 50 mg/ml thermolysin, which is reported to digest PrP
C
without affecting protease sensitive PrP
Sc [28,29]. The digested
supernatant was concentrated by centrifugation with a 10 kDa
filter (Sartorius vivaspin) and adjusted to an equivalent of
10
6 cells/ml. Samples were heated to 95uC for 5 minutes and
tested in a PrP specific enzyme-linked immunosorbent assay
(ELISA). Uninfected N2a, GT1 or SMB-PS cells were used as
controls.
Primary neuronal cultures
Primary cortical neurones were prepared from the brains of
mouse embryos (day 15.5) after mechanical dissociation [23].
Neuronal precursors were plated (2610
5 cells/well in 48 well
plates pre-coated with 5 mg/ml poly-L-lysine) in Ham’s F12
medium containing 5% FCS for 2 hours. Cultures were shaken
(600 r.p.m for 5 minutes) and non-adherent cells removed by 2
washes in PBS. Neurones were subsequently grown in neurobasal
medium (NBM) containing B27 components (Invitrogen, Paisley,
UK) for 7 days. Immunolabelling studies showed that after 7 days
cultures contained less than 5% glial cells (,3% GFAP positive
and less than 1% MAC-1 positive cells). Hippocampal neurones
were prepared from the brains of adult mice as described [30].
Briefly, hippocampi were dissected from the adult brain tissue and
triturated in Ham’s F12 containing 5% FCS, 0.35% glucose,
0.025% trypsin, and 0.1% type IV collagenase (Invitrogen). After
30 minutes at 37uC, the cells were triturated with a 1 ml pipette
and passed through a 100 mM cell strainer. Cells were washed
twice in Ham’s F12 medium containing 5% FCS and plated in 48
well plates pre-coated with 5 mg/ml poly-L-lysine (2610
5 cells/
well) for 24 hours. Cultures were shaken (600 r.p.m for 5 minutes)
to remove non-adherent cells, washed twice with PBS and cultured
in NBM containing B27 components and 10 ng/ml glial-derived
neurotrophic factor (Sigma) for 7 days. Neurones were subse-
quently pre-treated with test compounds (glimepiride, glipizide,
glibenclamide, p-chloromercuriphenylsulphonate (p-CMPS) or PI-
PLC derived from Bacillus cereus, obtained from Sigma) and washed
before the addition of PrP peptides or further analysis. Stock
solutions of drugs were prepared in di-methyl sulphoxide (DMSO)
and diluted on the day of use, vehicle controls were equivalent
dilutions of DMSO. The survival of neurones was determined 5
days later using 25 mM thiazlyl blue tetrazolium (MTT); neuronal
survival was reported as a percentage of control, vehicle treated
neurones.
Cell extracts
After treatment, cells were washed twice in PBS and
homogenised in an extraction buffer containing 10 mM Tris-
HCl, 100 mM NaCl, 10 mM EDTA, 0.5% Nonidet P-40, 0.5%
sodium deoxycholate and 0.2% sodium dodecyl sulphate (SDS) at
10
6 cells/ml and nuclei and large fragments were removed by
centrifugation (3006g for 5 minutes). Mixed protease inhibitors
were added to cell extracts where appropriate.
Measurement of cell surface PrP
C
The amount of PrP
C expressed at the cell surface was
determined by two methods. In the first, 10
6 treated neurones
were subsequently pulsed with PBS containing 50 mg/ml of
membrane-impermeable sulfo-biotin-X-NHS (Pierce, Cramling-
ton, UK) for 10 minutes. Cells were then washed 4 times with ice
cold PBS containing 10% FCS to remove unbound biotin and the
amount of biotinylated PrP
C measured in a modified ELISA.
Maxisorb Immunoplates (Nunc, Roskilde, Denmark) were pre-
coated with 10 mg/ml streptavidin (Sigma) and blocked with 10%
milk powder. Samples were added for 1 hour and the amount of
bound biotinylated PrP
C was determined by incubation with the
PrP-specific mAb ICSM18, anti-mouse IgG-alkaline phosphate
and 1 mg/ml 4-nitrophenyl phosphate. Absorbance was measured
at 450 nm and the amount of biotinylated PrP
C was calculated by
reference to a standard curve of biotinylated recombinant PrP
(Prionics, Zurich, Switzerland). The second method involved
incubating treated cells with 0.2 units of PI-PLC/10
6 cells for
1 hour at 37uC. PI-PLC acts on the GPI anchored proteins
including PrP
C at the cell surface. The amount of PrP
C released
into the supernatant following PI-PLC digestion was measured by
PrP ELISA.
Reverse phase chromatography of PrP
C
Supernatants from glimepiride treated primary cortical neu-
rones were applied to C18 columns (Waters, Elstree, UK). For
comparison, PrP
C from cell extracts and PrP
C that had been
digested with PI-PLC (0.2 units/ml for 1 hour at 37uC) were also
added to C18 columns. Proteins were eluted by reverse phase
chromatography under a gradient of acetonitrile in water and
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lyophilised, solubilised in extraction buffer and tested in a PrP
ELISA.
PrP ELISA
The amount of PrP in cell extracts/supernatants was measured
by ELISA as described [31,32]. Maxisorb Immunoplates were
coated with a PrP-specific mAb (ICSM18 which recognises amino
acids 146 to 159 of murine PrP). Samples were applied and
detected with biotinylated mAb ICSM35 (which recognises a
region between amino acids 91 and 110). This was detected using
extravidin-alkaline phosphatase and 1 mg/ml 4-nitrophenyl
phosphate. Absorbance at 450 nm was measured on a microplate
reader and the amount of PrP calculated by reference to a
standard curve of recombinant murine PrP (Prionics); its limit of
detection was 0.05 ng/ml.
The amount of PrP82–146 in cell extracts was also determined
by ELISA. Maxisorb Immunoplates were coated with 0.5 mg/ml
of mouse mAb 3F4 (reactive with residues 109–112 of human PrP
(Abcam, Chandler’s Ford, UK), this mAb does not bind to murine
PrP [33]. Samples were applied and detected with biotinylated
ICSM35 (D-gen), followed by extravidin-alkaline phosphatase and
1 mg/ml 4-nitrophenyl phosphate. Absorbance was measured on
a microplate reader at 450 nm and the amount of PrP82–146 was
calculated by reference to a standard curve of PrP82–146.
Activated cPLA2 ELISA
The activation of cPLA2 is accompanied by phosphorylation of
the 505 serine residue, which can be measured by phospho-specific
antibodies. The amount of activated cPLA2 in cell extracts was
measured by ELISA as described [32]. Nunc Maxisorb Immuno-
plates were coated with 0.5 mg/ml of mouse mAb anti-cPLA2,
clone CH-7 (Upstate, Milton Keynes, UK) for 1 hour and blocked
with 10% FCS. Samples were incubated for 1 hour and the
amount of activated cPLA2 was detected using a rabbit polyclonal
anti-phospho-cPLA2 (Cell Signalling Technology). Bound anti-
bodies were then detected using biotinylated anti-rabbit IgG
(Dako), extravidin-alkaline phosphatase and 1 mg/ml 4-nitrophe-
nyl phosphate. Absorbance was measured at 450 nm and the
amount of activated cPLA2 present calculated by reference to a
standard curve, using nonlinear regression. Samples were
expressed as ‘‘units cPLA2’’, 100 units being defined as the
amount of cPLA2 in 10
6 untreated cortical neurones. A standard
curve ranging from 100 to 1.56 units/well was prepared from this
sample using doubling dilutions.
PGE2 assay
The amount of PGE2 produced by cells was determined by
using an enzyme-immunoassay kit (Amersham Biotech, Amer-
sham, UK). The detection limit of this assay is 20 pg/ml.
Peptides
Peptides containing amino acids 82 to 146 of the human PrP
protein (PrP82–146) corresponding to a PrP fragment found in
certain prion-infected human brains [22], and a control peptide
(PrP82–146scrambled) were synthesised by solid-phase chemistry
and purified by reverse-phase HPLC. Stock solutions were thawed
on the day of the experiment and sonicated for 10 minutes before
addition to cells.
Statistical Analysis
Comparison of treatment effects was carried out using one and
two way analysis of variance techniques as appropriate.
Results
Glimepiride reduced PrP
C at the surface of neurones
Since glimepiride has been reported to stimulate the release or
redistribution of GPI-anchored proteins in adipocytes [17,20], its
effect on PrP
C in cortical neurones was examined. Treatment of
neurones for 1 hour with glimepiride reduced the amount of PrP
C
in cell extracts in a dose-dependent manner (Figure 1). This effect
of glimepiride was not shared by glibenclamide or glipizide, two
other sulphonylureas used to treat diabetes mellitus, which did not
alter the PrP
C content of neurones. The reduction in the PrP
C
content of neurones achieved following treatment with 5 mM
glimepiride (19.6 ng/10
6 cells61.7 compared with 28.563.4,
n=12, P,0.01) was similar in magnitude to that observed in
neurones treated with 0.2 units PI-PLC/ml (19.2 ng/10
6
cells62.8 compared with 28.563.4, n=12, P,0.01), results
consistent with the hypothesis that glimepiride activates an
endogenous GPI-PLC. Higher concentrations of glimepiride or
PI-PLC, or prolongation of treatment to 4 hours, did not cause
any further reduction in the neuronal PrP
C content. Neither
glimepiride nor PI-PLC affected the survival of neurones as
measured by thiazyl blue tetrazolium.
Cortical neurones treated with glimepiride for 1 hour were
subsequently pulsed with a membrane-impermeable biotin ester
to determine whether glimepiride affects the amount of PrP
C
expressed at the cell surface. Treatment with glimepiride, but not
glipizide or glibenclamide, reduced the amount of biotinylated
PrP
C in cell membranes (Figure 2A). Treatment with 0.2 units PI-
PLC/ml also reduced the amount of biotinylated PrP
C in cell
membranes (0.6 ng/10
6 cells60.2 compared to 7.461.1, n=9,
P,0.01). Time course studies showed that the effect of
glimepiride on the expression of PrP
C on the surface of cortical
neurones was transient. Thus the amount of PrP
C labelled with
cell-impermeable biotin inn e u r o n e sp u l s e dw i t h5mMg l i m e p i r -
ide for 1 hour remained low for 2 hours after the cessation of
glimepiride treatment and only returned to the levels seen in
untreated cells after 12 hours (Figure 2B). When these exper-
iments were conducted in the presence of 20 mg/ml cyclohex-
Figure 1. Glimepiride reduced neuronal PrP
C expression. The
amount of PrP
C in whole cell extracts from primary cortical neurones
treated for 1 hour with different concentrations of glimepiride (N),
glibenclamide (#) or glipizide (&) as shown. Values shown are the
mean average amount of PrP
C in neuronal extracts (ng/10
6 cells) 6 SD,
n=12.
doi:10.1371/journal.pone.0008221.g001
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C
to the cell surface was delayed, indicating that the PrP
C that
appeared at the surface of glimepiride treated cells had been
newly synthesised rather than rerouted from an existing
intracellular pool.
Glimepiride stimulated the release of PrP
C from neurones
Next we sought to determine if glimepiride stimulated the
release of PrP
C from the cell by measuring the amount of PrP
C in
the supernatants of cultured neurones. The addition of
glimepiride for 1 hour, but not glibenclamide or glipizide,
increased the amount of PrP
C released into cell supernatant
(Figure 3A). Similarly, the addition of 0.2 units PI-PLC/ml for
1 hour increased the amount of PrP
C in the supernatants of
neurones (9.9 ng/10
6 cells61.1 compared to 0.660.3 in
untreated supernatants, n=9, P,0.01). We noted that glimepir-
ide treatment caused the release of specific GPI-anchored
proteins. Thus, while digestion with 0.2 units PI-PLC/ml
released both PrP
C and Thy-1 from neurones, treatment with
5 mM glimepiride released PrP
C b u td i dn o tr e l e a s eT h y - 1( d a t a
not shown).
PrP
C can be released from cells by different mechanisms
[11,34,35,36,37]. Therefore we sought evidence that the PrP
C in
the supernatant of glimepiride treated cells was released following
its digestion by a GPI-PLC. When cell-associated PrP
C containing
an intact GPI anchor was bound to a C18 column and exposed to
acetonitrile:water gradients, it was found in those fractions
containing 70–76% acetonitrile. In contrast, cell-associated PrP
C
molecules that had been digested by 0.2 units PI-PLC/ml did not
bind to C18 columns. The PrP
C in supernatants from glimepiride
treated neurones did not bind to C18 columns indicating that
these PrP
C molecules had lost their hydrophobic acyl chains,
consistent with the view that they had been digested by GPI-PLC
(Figure 3B). Next we sought to determine if the effect of
glimepiride could be reversed by the addition of p-CMPS, which
inhibited GPI-PLC [38]. Whereas treatment with as much as
500 mM p-CMPS alone had no detectable effect on cell surface
PrP
C (not shown), addition of p-CMPS to cortical neurones treated
with 5 mM glimepiride increased the amount of PrP
C at their
surface to control levels (Figure 4), confirming that glimepiride
activates an endogenous GPI-PLC.
Figure 2. Glimepirde reduced the amount of PrP
C at the surface
of neurones. (A) The amount of cell surface PrP
C on neurones treated
for 1 hour with different concentrations of glimepiride (N), glibencla-
mide (#) or glipizide (&) as shown. Values shown are the mean
average amount of biotinylated PrP
C in cell extracts (ng/10
6 cells) 6 SD,
n=9. (B) The amount of cell surface PrP
C in cell extracts from cortical
neurones taken at different time points after the addition of 5 mM
glimepiride alone (%) or a mixture containing 5 mM glimepiride and
20 mg/ml cycloheximide (&) as shown. Values shown are the mean
average amount of biotinylated PrP
C in cell extracts (ng/10
6 cells) 6 SD,
n=9.
doi:10.1371/journal.pone.0008221.g002
Figure 3. Glimepiride released PrP
C from cortical neurones. (A)
The amount of PrP
C in the supernatant of cortical neurones treated for
1 hour with different concentrations of glimepiride (N), glibenclamide
(#) or glipizide (&). Values shown are the mean average amount of
soluble PrP
C (ng/10
6 cells) 6 SD, n=9. (B) The amount of PrP
C
molecules eluted from C18 columns following elution with a gradient of
acetonitrile in water containing 0.1% TFA. Fractions eluted from C18
columns loaded with whole cell extracts (#) or with supernatants from
cortical neurones treated with 5 mM glimepiride (N). Values shown are
the mean average amount of PrP
C (ng/ml) 6 SD, n=6.
doi:10.1371/journal.pone.0008221.g003
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Sc content of prion infected
neuronal cells
Since the cell surface is a possible site of the conversion of PrP
C
to PrP
Sc [12,13] the effect of glimepiride on the PrP
Sc content of
ScGT1 cells was determined. Treatment with 5 mM glimepiride
for 1 hour released PrP molecules from ScGT1 cells into the
supernatant (8.4 ng/10
6 cells). These PrP molecules were sensitive
to digestion with 5 mg/ml proteinase K which reduced the PrP
content to less than 0.05 ng/10
6 cells, indicating that the PrP
released was PrP
C or protease-sensitive PrP
Sc. The PrP molecules
were also sensitive to digestion with 50 mg/ml thermolysin
(following digestion the PrP content of supernatants was reduced
to less than 0.05 ng/10
6 cells) indicating that the PrP released was
PrP
C rather than protease-sensitive PrP
Sc [29]. Next, the effect of
longer term treatment was examined. Twice daily treatment for 7
days with glimepiride, but not glibenclamide, caused a dose-
dependent reduction in the amount of PrP
Sc in ScGT1 cells
(Figure 5A). We were unable to detect PrP
Sc in ScGT1 cells
treated with 5 mM glimepiride for 7 days. Moreover, these cells
remained free of PrP
Sc when grown for a further month after the
cessation of treatment. The amount of PrP
Sc in ScGT1 cells
treated for 7 days with increasing concentrations of glimepiride
showed a significant correlation with the amount of PrP
C released
from the surface of glimepiride treated ScGT1 cells 1 hour after
treatment, Pearson’s coefficient=0.868, P,0.01 (Figure 5B). This
effect of glimepiride was not cell line specific as similar dose-
dependent reductions in PrP
Sc content were observed in both
ScN2a and SMB cells (Figure 6A and B).
Recent studies showed that glimepiride treatment of adipo-
cytes released GPI anchored proteins in exosomes [19,39]. Since
PrP
Sc can also be released from prion-infected rabbit kidney cells
in exosomes [34], the possibility that glimepiride might also
stimulate exosome formation and the release of PrP
Sc from prion-
infected neuronal cells was examined. The amount of PrP
Sc
present insupernatants from ScGT1, ScN2a or SMB cells treated
with 5 mM glimepiride for 7 days, was measured by ELISA.
Treatment with glimepiride significantly reduced the amount of
PrP
Sc in supernatants collected from ScGT1 cells (0.4 ng PrP
Sc/
10
6 cells60.3 compared with 1.97 ng60.58, n=9, P,0.01),
SMB cells (0.3 ng PrP
Sc/10
6 cells60.4 compared with
1.21 ng60.28, n=9, P,0.01) and ScN2a cells (0 ng PrP
Sc/10
6
cells compared with 0.45 ng60.01, n=9, P,0.01). These data
indicated that the reduction of cell associated PrP
Sc observed
after glimepiride treatment was not related to a stimulation of
PrP
Sc release.
Glimepiride treated neurones are resistant to PrP82-146
toxicity
The addition of PrP82–146 reduced the survival of cortical
neurones [23,24]. Pre-treatment with 5 mM glimepiride protected
cortical neurones against the toxic effect of PrP82–146 (Figure 7A).
The concentration of PrP82–146 required to kill 50% of neurones
(LD50) was at least 20 times greater, from 10 mM in mock-treated
neurones to more than 200 mM PrP82–146 in glimepiride treated
cells. The protective effect of glimepiride was dose-dependent
(Figure 7B) and was not observed with glipizide. This effect of
glimepiride was not specific for cortical neurones, the survival of
hippocampal neurones incubated with 5 mM PrP82–146 was also
significantly increased by pre-treatment with 5 mM glimepiride
Figure 4. Glimepiride induced release of PrP
C is reversed by p-
CMPS. The amount of PrP
C at the surface of cortical neurones treated
for 1 hour with 5 mM glimepiride alone (%) or with combinations
containing 5 mM glimepiride and different concentrations of p-CMPS as
shown (&). Values shown are the mean average amount of
biotinylated-PrP
C (ng/10
6 cells) 6 SD, n=8.
doi:10.1371/journal.pone.0008221.g004
Figure 5. Glimepiride reduced the PrP
Sc content of ScGT1 cells.
(A) The amount of PrP
Sc in ScGT1 cells treated for 7 days with different
concentrations of glimepiride (&) or with glibenclamide (%). Values
shown are the mean average amount of PrP
Sc (ng/10
6 cells) 6 SD, n=12.
(B) Correlation between the amount of PrP
C at the surface of ScGT1 cells
after 1 hour incubation with different concentrations of glimepiride and
the amount of PrP
Sc in ScGT1 cells following treatment for 7 days.
doi:10.1371/journal.pone.0008221.g005
Glimepiride and Prions
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Glimepiride treated neurones were not resistant to all neurotoxins
and did not protect against staurosporine (data not shown). The
protective effect of glimepiride was dependent on pre-treatment
and was not observed when 5 mM glimepiride was added 1 hour
after addition of 20 mM PrP82–146 (41% cell survival67
compared with 38%65, n=10, P=0.4). It was also transient
and was lost after 12 hours (Figure 8). The return of sensitivity to
the toxic action of PrP82–146 coincided with the return of PrP
C to
the surface of the neurones as shown in Figure 2.
Since glimepiride activates an endogenous GPI-PLC [16,17] the
effects of PI-PLC on neuronal responses to PrP82–146 were also
examined. Pre-treatment with 0.2 units PI-PLC/ml was found to
increase the survival of cortical neurones subsequently incubated
with PrP82–146 (Figure 9A). Next we tested the hypothesis that
the protective effect of glimepiride was due to activation of an
endogenous GPI-PLC. First we showed that pre-treatment with a
GPI-PLC inhibitor (500 mM p-CMPS) did not affect the survival
of neurones subsequently incubated with PrP82–146. Next, we
showed that the protective effect of 5 mM glimepiride was reversed
by the inclusion of 500 mM p-CMPS indicating that protection
was dependent upon activation of an endogenous GPI-PLC
(Figure 9B).
Glimepiride reduced the binding of PrP82–146 by
neurones
Since PrP
C acts as a receptor for PrP peptides [40], the effect of
glimepiride on the binding of 10 mM PrP82–146 to cortical
neurones was examined. The amount of PrP82–146 bound was
time-dependent over 60 minutes. Neurones pre-treated with 5 mM
glimepiride bound significantly less PrP82–146 than mock-treated
neurones (Figure 10). It was noted that glimepiride treatment did
not completely block the binding of PrP82–146 to neurones. Thus,
60 minutes after the addition of 10 mM PrP82–146, glimepiride
treated neurones bound 6.2 nM PrP82–14660.8 compared to
9.9 nM PrP82–14660.8 in controls (n=8). Similar results were
obtained when neurones were pre-treated with 0.2 units PI-PLC/
ml, which after 60 minutes had bound 5.3 nM PrP82–14660.7,
n=8.
Glimepiride reduced activation of cPLA2 by PrP82–146
Unregulated activation of PLA2 is recognized as a key event in
some neurodegenerative diseases [41,42,43]. The activation of
PLA2 is the first step in the production of eicosanoids, docosanoids
and platelet activating factors, high concentrations of which cause
Figure 6. Glimepiride reduced the PrP
Sc content of prion-
infected neuronal cells. (A) The amount of PrP
Sc in ScN2a cells
following treatment for 7 days with control medium (%) or with
different concentrations of glimepiride (&). Values shown are the mean
average amount of PrP
Sc (ng/10
6 cells) 6 SD, n=12. (B) The amount of
PrP
Sc in SMB cells treated for 7 days with control medium (%) or with
different concentrations of glimepiride (&). Values shown are the mean
average amount of PrP
Sc (ng/10
6 cells) 6 SD, n=12.
doi:10.1371/journal.pone.0008221.g006
Figure 7. Glimepiride protects cortical neurones against
PrP82–146. (A) The survival of cortical neurones pre-treated for
1 hour with control medium (N) or with 5 mM glimepiride (#) and
incubated with varying concentrations of PrP82–146 for 5 days. Values
shown are the mean average neuronal survival 6 SD, n=12. (B) The
survival of cortical neurones pre-treated for 1 hour with varying
concentrations of glimepiride (#) or glipizide (N) and incubated with
20 mM PrP82–146 for 5 days. Values shown are the mean average
neuronal survival 6 SD, n=9.
doi:10.1371/journal.pone.0008221.g007
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addition of PrP82–146 increased the amount of activated cPLA2 in
neurones. Treatment with 5 mM glimepiride alone did not alter
the amount of activated cPLA2 in cortical neurones (100 units
activated cPLA268 compared to 97610, n=9, P=0.4), but
greatly reduced the activation of cPLA2 induced by PrP82–146
(Figure 11A); treatment with 5 mM glibenclamide or 5 mM
glipizide had no effect. Digestion of neurones with PI-PLC also
reduced activation of cPLA2 induced by PrP82–146. To confirm
the effect of glimepiride on PrP82–146 induced PLA2 activation,
neuronal PGE2 production was also measured. As would be
predicted, PGE2 production from neurones pre-treated with 5 mM
glimepiride, or with PI-PLC, was significantly lower than that of
untreated neurones after incubation with 10 mM PrP82–146 for
24 hours (Figure 11B).
Discussion
In this study we report that treatment with glimepiride reduced
the amount of PrP
C expressed at the surface of primary cortical
neurones, neuronal cells and prion-infected neuronal cells.
Subsequently, glimepiride treatment significantly reduced the
amount of PrP
Sc within 3 prion-infected neuronal cell lines
(ScGT1, SMB and ScN2a cells) and glimepiride treated cortical
neurones showed increased resistance to the toxic effects of PrP82–
146. The protective effect of glimepiride was accompanied by
reduced binding of PrP82–146 to neurones, reduced activation of
cPLA2 and PGE2 production. These effects of glimepiride were
observed at physiological concentrations [44], however they were
not shared by 2 other sulphonylureas used to treat diabetes,
glibenclamide or glipizide.
The cellular location of PrP
C is controversial and although PrP
C
is expressed at the cell surface, it is also found within cells [45,46].
Our findings support the view that a proportion of the PrP
C in
cortical neurones is in an intracellular pool, since it resisted both
digestion with PI-PLC and biotinylation with a cell impermeable
biotin-conjugate. Treatment of cortical neurones, neuronal cells
and prion-infected neuronal cells with glimepiride reduced the
amount of PrP
C expressed at the cell surface and caused its release
into the supernatant whereas the amount present in cell extracts
was reduced by about a third. The release of PrP
C into
supernatants may occur as a consequence of exosome formation,
or following digestion by phospholipases and proteases
[11,34,35,36,37]. Glimepiride activates an endogenous GPI-PLC
in adipocytes [18] and many of its effects on neurones were
replicated by the addition of PI-PLC. In addition, glimepiride
induced release of PrP
C was reversed by the inclusion of p-CMPS,
an inhibitor of GPI-PLC. Whereas PrP
C bound to C18 columns,
PrP
C released from glimepiride treated cells did not bind,
consistent with the loss of hydrophobic acyl chains. Why
glimepiride affects PrP
C at the surface of neurones, but not
intracellular PrP
C, is unclear. It is possible that glimepiride does
not penetrate the cell, an alternative explanation may be that GPI-
PLC is associated with cell surface PrP
C, but is absent from
intracellular stores of PrP
C.
Glimepiride treatment did not affect all GPI-anchored proteins.
Thus, while digestion of neurones with PI-PLC released several
GPI-anchored proteins into the supernatant, including PrP
C and
Thy-1, glimepiride treatment released PrP
C but not Thy-1
(unpublished data). This specific effect of glimepiride may be
due to the activation of an endogenous GPI-PLC that is closely
Figure 8. Protective effect of glimepiride is transient. The
survival of vehicle treated cortical neurones (%) or cortical neurones
pre-treated with 5 mM glimepiride for the time periods as shown (&)
and incubated with 20 mM PrP82–146 for a further 5 days. Values shown
are the mean average neuronal survival 6 SD, n=12.
doi:10.1371/journal.pone.0008221.g008
Figure 9. Digestion with PI-PLC protects neurones against
PrP82–146. (A) The survival of cortical neurones pre-treated for 1 hour
with 0.2 units PI-PLC/ml (#) or with control medium (N) and incubated
with varying concentrations of PrP82–146 as shown. Values shown are
the mean average neuronal survival 6 SD, n=9. (B) The survival of
cortical neurones pre-treated for 1 hour with a vehicle control (N), with
5 mM glimepiride (#), with 500 mM p-CMPS (%) or with a combination
of 5 mM glimepiride and 500 mM p-CMPS (&) and incubated with
varying concentrations of PrP82–146. Values shown are the mean
average neuronal survival 6 SD, n=9.
doi:10.1371/journal.pone.0008221.g009
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C, but
not with others including Thy-1 or CD55 which occupy separate
domains upon the cell surface [47]. An alternative explanation is
that CD55 and Thy-1 may contain GPI anchors that are resistant
to endogenous GPI-PLC.
The precise cellular location in which PrP
C is converted to
PrP
Sc remains controversial with advocates for the endosomal
recycling compartment [48,49]. However, anti-PrP antibodies
reduced PrP
Sc formation, suggesting that conversion occurs either
at the cell surface, or after PrP
C has been internalised from the cell
surface [13,15,50]. Such observations indicate that surface
expression of PrP
C is a prerequisite for PrP
Sc formation and that
glimepiride reduced PrP
Sc formation by shedding PrP
C from the
cell surface. Our finding that glimepiride treatment released PrP
molecules from ScGT1 cells raised concerns that glimepiride
might cause the release of PrP
Sc and facilitate its spread
throughout the brain. However, all PrP released from cells within
1 hour of treatment was sensitive to digestion with proteinase K.
Although the presence of proteinase K sensitive PrP
Sc is well
documented [51], the released PrP was also sensitive to digestion
with thermolysin which has been reported to digest PrP
C but not
PrP
Sc [29]. Collectively these results indicate that the PrP released
from ScGT1 cells was PrP
C. The longer term effects of glimepiride
treatment showed that twice daily treatment for 7 days caused a
dose-dependent reduction in the PrP
Sc content of ScGT1, ScN2a
and SMB cells. It also reduced the amount of PrP
Sc released into
supernatants over this period, excluding the possibility that the
reduction in cell-associated PrP
Sc was due to glimepiride induced
the release of PrP
Sc from cells. Our findings are consistent with the
hypothesis that glimepiride acts by limiting the supply of PrP
C to
cellular sites that are essential for PrP
Sc formation.
Glimepiride treatment of cortical neurones affected cell surface
PrP
C but not intracellular PrP
C. Similar results were obtained with
GT1 and ScGT1 cells in which approximately 70% of PrP
C
molecules remained after treatment with glimepiride or PI-PLC
and about the same amount resisted labelling by membrane
impermeable biotin. These results suggest that PrP
Sc is formed
from a subset of PrP
C molecules that recycle to and from the cell
surface. Perhaps more significantly they indicate that the
intracellular PrP
C molecules were poor substrates for conversion
to PrP
Sc. In addition, the repopulation of surface PrP
C in
glimepiride treated cells was from newly synthesised PrP
C rather
than from the intracellular pool, as it was delayed by the inclusion
of the protein synthesis inhibitor cycloheximide. We conclude that
there are at least 2 pools of PrP
C: one that consists of PrP
C
molecules that recycle to and from the cell surface and are
susceptible to conversion to PrP
Sc and another pool of PrP
C
molecules that are mostly intracellular and are not readily
converted to PrP
Sc suggesting that they follow different trafficking
pathways. Such results are consistent with reports that altering the
trafficking of PrP
C alters PrP
Sc formation [52,53].
Pre-treatment with glimepiride protected cortical and hippo-
campal neurones against the toxic action of PrP82–146; it
increased the LD50 of PrP82–146 by more than 20 fold, from
10 mM to over 200 mM. However, glimepiride treated neurones
remained sensitive to staurosporine (data not shown). The
protective effect of glimepiride required pre-treatment; glimepiride
did not rescue neurones that had been incubated with PrP82–146
Figure 10. Glimepiride reduced the binding of PrP82–146 to
neurones. The amount of PrP82–146 in cell extracts from cortical
neurones pre-treated for 1 hour with a vehicle control (%) or with 5 mM
glimepiride (&) and exposed to 10 mM PrP82–146 for different times
periods as shown. Values shown are the mean average amount of
PrP82–146 (mM) 6 SD, n=9.
doi:10.1371/journal.pone.0008221.g010
Figure 11. Glimepiride reduced the activation of cPLA2 by
PrP82–146. The amount of activated cPLA2 in cell extracts from
cortical neurones pre-treated for 1 hour with a vehicle control (N)5mM
glimepiride (#) or PI-PLC (&) and incubated with varying concentra-
tions of PrP82–146 for 24 hours. Values shown are the mean average
amount of activated cPLA2 (units) 6 SD, n=12. (B) The amount of PGE2
in cell extracts from cortical neurones pre-treated for 1 hour with
control medium (%), 5 mM glimepiride (&) or PI-PLC (striped bars) and
incubated with control medium or 10 mM PrP82–146. Values shown are
the mean average amount of PGE2 (pg/ml) 6 SD, n=9.
doi:10.1371/journal.pone.0008221.g011
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146 induced toxicity. Moreover, the protective effect of glimepir-
ide was transient. Restoration of PrP
C to the surface of neurones
following glimepiride treatment was associated with their
increased sensitivity of neurones to PrP82–146. Neurones treated
with PI-PLC were also protected against PrP82–146 suggesting
that glimepiride-mediated neuroprotection was due to activation
of GPI-PLC. This hypothesis was strengthened by the finding that
the protection induced by glimepiride was reversed following the
addition of the GPI-PLC inhibitor p-CMPS.
PrP
C has been proposed as a receptor for PrP peptides [40] and
glimepiride reduced the binding of PrP82–146 to neurones. It is
worth noting that although treatment with glimepiride or PI-PLC
significantly reduced the binding of PrP82–146 to neurones, these
cells still bound significant amounts of PrP82–146 (about 50% of
the binding of untreated cells) indicating that PrP82–146 can bind
to neurones via a PrP
C independent mechanism. Many proteins
have been proposed to be prion receptors [54] and it seems likely
that glimepiride treated cells express some of them, or that PrP82–
146 binds to cells independently of specific protein interactions.
Since the reduction in PrP82–146 binding alone did not fully
explain the protective effects of glimepiride, the effects of
glimepiride on PrP82–146 induced cell signalling were examined.
The unregulated activation of PLA2 is recognized as a key event in
some neurodegenerative diseases [41,42] and is the first step in the
production of eicosanoids, docosanoids and platelet activating
factors, high concentrations of which can cause glial activation,
synapse damage and neuronal death. Furthermore, PLA2 plays a
critical role in neurotoxicity caused by PrP peptides [55]. Our
experiments showed that PrP82–146 activated cPLA2 in neurones
and increased PGE2 production, a marker of PLA2 activation that
is increased in scrapie infected mice [56,57] and in the
cerebrospinal fluid of patients with CJD [58,59]. Pre-treatment
with glimepiride significantly reduced PrP82–146 induced activa-
tion of cPLA2 and the production of PGE2. Although the precise
mechanism is not clear, the activation of cPLA2 occurs in
cholesterol-sensitive lipid rafts [60,61]. Since glimepiride induced
digestion of GPI anchored proteins affects membrane cholesterol
in adipocytes [62] our results are consistent with the hypothesis
that glimepiride modifies lipid rafts required for cPLA2 activation.
Other studies suggest that the neurotoxicity of PrP peptides is
through the amplication of PrP
C associated signalling path-
ways [63] which may be downregulated following glimepiride
treatment.
Prion infection increased cholesterol in cell membranes [32].
Since the insulin receptor is found within lipid rafts [64] and
insulin signalling is cholesterol dependent [65,66], prion infection
induced changes in cell cholesterol may modify insulin signalling.
This is consistent with observations that prion infection affects
insulin and insulin-like growth factor receptors in cell lines [67,68]
and that scrapie infection induced diabetes mellitus in hamsters is
directly damaging the central nervous system, without affecting the
pancreas [69]. Thus, glimepiride treatment may also reverse
prion-induced effects on insulin signalling.
One important consequence of the effect of glimepiride on PrP
C
may be of relevance to the treatment of Alzheimer’s disease. PrP
C
was identified as a receptor that mediated the impairment of
synaptic plasticity induced by amyloid-b oligomers [70]. Thus, the
pharmacological regulation of PrP
C by glimepiride could provide a
new approach to the inhibition of amyloid-b mediated synapse
damage in Alzheimer’s disease patients.
New approaches to the treatment of neurodegenerative
conditions including prion diseases are urgently required. We
have demonstrated that treatment of neurones with glimepiride
caused the shedding of PrP
C from the cell surface through
activation of an endogenous GPI-PLC. Treatment reduced the
formation of PrP
Sc in prion-infected neuronal cell lines and
increased the survival of neurones incubated with PrP82–146.
Glimepiride treatment reduced both the amount of PrP82–146
ingested by neurones and PrP82–146 induced activation of cPLA2.
Our results suggest that glimepiride could prove beneficial in the
treatment of prion diseases.
Author Contributions
Conceived and designed the experiments: CB MS AW. Performed the
experiments: CB. Analyzed the data: CB MT LD MS AW. Contributed
reagents/materials/analysis tools: MT MS. Wrote the paper: CB MT LD
AW.
References
1. Prusiner SB (1998) Prions. ProcNatlAcadSciUSA 95: 13363–13383.
2. Pan KM, Baldwin M, Nguyen J, Gasset M, Serban A, et al. (1993) Conversion of
alpha-helices into beta-sheets features in the formation of the scrapie prion
proteins. ProcNatlAcadSciUSA 90: 10962–10966.
3. Prusiner SB, McKinley MP, Bowman KA, Bolton DC, Bendheim PE, et al.
(1983) Scrapie prions aggregate to form amyloid-like birefringent rods. Cell 35:
349–358.
4. Jeffrey M, Halliday WG, Bell J, Johnston AR, MacLeod NK, et al. (2000) Synapse
loss associated with abnormal PrP precedes neuronal degeneration in the scrapie-
infected murine hippocampus. NeuropatholApplNeurobiol 26: 41–54.
5. Prusiner SB (1982) Novel proteinaceous infectious particles cause scrapie.
Science 216: 136–144.
6. Barron RM, Campbell SL, King D, Bellon A, Chapman KE, et al. (2007) High
Titers of Transmissible Spongiform Encephalopathy Infectivity Associated with
Extremely Low Levels of PrPSc in Vivo. J Biol Chem 282: 35878–35886.
7. Bueler H, Aguzzi A, Sailer A, Greiner RA, Autenried P, et al. (1993) Mice
devoid of PrP are resistant to scrapie. Cell 73: 1339–1347.
8. Mallucci G, Dickinson A, Linehan J, Klohn PC, Brandner S, et al. (2003)
Depleting neuronal PrP in prion infection prevents disease and reverses
spongiosis. Science 302: 871–874.
9. Manson JC, Clarke AR, McBride PA, McConnell I, Hope J (1994) PrP gene
dosage determines the timing but not the final intensity or distribution of lesions
in scrapie pathology. Neurodegeneration 3: 331–340.
10. Stahl N, Borchelt DR, Hsiao K, Prusiner SB (1987) Scrapie prion protein
contains a phosphatidylinositol glycolipid. Cell 51: 229–240.
11. Stahl N, Borchelt DR, Prusiner SB (1990) Differential release of cellular and
scrapie prion proteins from cellular membranes by phosphatidylinositol-specific
phospholipase C. Biochemistry 29: 5405–5412.
12. Caughey B, Raymond GJ (1991) The scrapie-associated form of PrP is made
from a cell surface precursor that is both protease- and phospholipase-sensitive.
J Biol Chem 266: 18217–18223.
13. Enari M, Flechsig E, Weissmann C (2001) Scrapie prion protein accumulation
by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein
antibody. ProcNatlAcadSciUSA 98: 9295–9299.
14. Beringue V, Vilette D, Mallinson G, Archer F, Kaisar M, et al. (2004) PrPSc
Binding Antibodies Are Potent Inhibitors of Prion Replication in Cell Lines.
J Biol Chem 279: 39671–39676.
15. Peretz D, Williamson RA, Kaneko K, Vergara J, Leclerc E, et al. (2001)
Antibodies inhibit prion propagation and clear cell cultures of prion infectivity.
Nature 412: 739–743.
16. Movahedi S, Hooper NM (1997) Insulin stimulates the release of the glycosyl
phosphatidylinositol-anchored membrane dipeptidase from 3T3-L1 adipocytes
through the action of a phospholipase C. Biochem J 326 (Pt 2): 531–537.
17. Mu ¨ller G, Dearey EA, Punter J (1993) The sulphonylurea drug, glimepiride,
stimulates release of glycosylphosphatidylinositol-anchored plasma-membrane
proteins from 3T3 adipocytes. Biochem J 289 (Pt 2): 509–521.
18. Mu ¨ller G, Dearey EA, Korndorfer A, Bandlow W (1994) Stimulation of a
glycosyl-phosphatidylinositol-specific phospholipase by insulin and the sulfonyl-
urea, glimepiride, in rat adipocytes depends on increased glucose transport. J Cell
Biol 126: 1267–1276.
19. Mu ¨ller G, Jung C, Straub J, Wied S, Kramer W (2009) Induced release of
membrane vesicles from rat adipocytes containing glycosylphosphatidylinositol-
anchored microdomain and lipid droplet signalling proteins. Cellular Signalling
21: 324–338.
20. Mu ¨ller G, Wied S, Walz N, Jung C (2008) Translocation of Glycosylpho-
sphatidylinositol-Anchored Proteins from Plasma Membrane Microdomains to
Glimepiride and Prions
PLoS ONE | www.plosone.org 9 December 2009 | Volume 4 | Issue 12 | e8221Lipid Droplets in Rat Adipocytes Is Induced by Palmitate, H2O2, and the
Sulfonylurea Drug Glimepiride. Mol Pharmacol 73: 1513–1529.
21. Brandner S, Isenmann S, Raeber A, Fischer M, Sailer A, et al. (1996) Normal
host prion protein necessary for scrapie-induced neurotoxicity. Nature 379:
339–343.
22. Salmona M, Morbin M, Massignan T, Colombo L, Mazzoleni G, et al. (2003)
Structural properties of Gerstmann-Straussler-Scheinker disease amyloid
protein. JBiolChem 278: 48146–48153.
23. Bate C, Salmona M, Diomede L, Williams A (2004) Squalestatin cures prion-
infected neurones and protects against prion neurotoxicity. JBiolChem 279:
14983–14990.
24. Fioriti L, Angeretti N, Colombo L, De Luigi A, Colombo A, et al. (2007)
Neurotoxic and Gliotrophic Activity of a Synthetic Peptide Homologous to
Gerstmann-Straussler-Scheinker Disease Amyloid Protein. J Biol Chem 27:
1576–1583.
25. Taraboulos A, Raeber A, Borchelt D, Serban D, Prusiner S (1992) Synthesis and
trafficking of prion proteins in cultured cells. Mol Biol Cell 3: 851–863.
26. Schatzl HM, Laszlo L, Holtzman DM, Tatzelt J, DeArmond SJ, et al. (1997) A
hypothalamic neuronal cell line persistently infected with scrapie prions exhibits
apoptosis. JVirol 71: 8821–8831.
27. Birkett CR, Hennion RM, Bembridge DA, Clarke MC, Chree A, et al. (2001)
Scrapie strains maintain biological phenotypes on propagation in a cell line in
culture. EMBO J 20: 3351–3358.
28. Owen JP, Rees HC, Maddison BC, Terry LA, Thorne L, et al. (2007) Molecular
profiling of ovine prion diseases by using thermolysin-resistant PrPSc and
endogenous C2 PrP fragments. J Virol 81: 10532–10539.
29. Cronier S, Gros N, Tattum MH, Jackson GS, Clarke AR, et al. (2008) Detection
and characterization of proteinase K-sensitive disease-related prion protein with
thermolysin. Biochem J 416: 297–305.
30. Brewer GJ (1997) Isolation and culture of adult rat hippocampal neurons.
J Neurosci Meth 71: 143–155.
31. Wadsworth JDF, Joiner S, Linehan JM, Cooper S, Powell C, et al. (2006)
Phenotypic heterogeneity in inherited prion disease (P102L) is associated with
differential propagation of protease-resistant wild-type and mutant prion protein.
Brain 129: 1557–1569.
32. Bate C, Tayebi M, Williams A (2008) Sequestration of free cholesterol in cell
membranes by prions correlates with cytoplasmic phospholipase A2 activation.
BMC Biol 6: 8.
33. Kascsak RJ, Rubenstein R, Merz PA, Tonna-DeMasi M, Fersko R, et al. (1987)
Mouse polyclonal and monoclonal antibody to scrapie-associated fibril proteins.
J Virol 61: 3688–3693.
34. Fevrier B, Vilette D, Archer F, Loew D, Faigle W, et al. (2004) Cells release
prions in association with exosomes. ProcNatlAcadSciUSA 101: 9683–9688.
35. Vella LJ, Sharples RA, Lawson VA, Masters CL, Cappai R, et al. (2007)
Packaging of prions into exosomes is associated with a novel pathway of PrP
processing. J Pathol 211: 582–590.
36. Parkin ET, Watt NT, Turner AJ, Hooper NM (2004) Dual mechanisms for
shedding of the cellular prion protein. JBiolChem.
37. Borchelt DR, Rogers M, Stahl N, Telling G, Prusiner SB (1993) Release of the
cellular prion protein from cultured cells after loss of its glycoinositol
phospholipid anchor. Glycobiology 3: 319–329.
38. Stanton JD, Rashid MB, Mensa-Wilmot K (2002) Cysteine-less glycosylpho-
sphatidylinositol-specific phospholipase C is inhibited competitively by a thiol
reagent: evidence for glyco-mimicry by p-chloromercuriphenylsulphonate.
Biochem J 366: 281–288.
39. Mu ¨ller G, Over S, Wied S, Frick W (2008) Association of (c)AMP-Degrading
Glycosylphosphatidylinositol-Anchored Proteins with Lipid Droplets Is Induced
by Palmitate, H2O2 and the Sulfonylurea Drug, Glimepiride, in Rat Adipocytes.
Biochemistry 47: 1274–1287.
40. Brown DR, Herms J, Kretzschmar HA (1994) Mouse cortical cells lacking
cellular PrP survive in culture with a neurotoxic PrP fragment. Neuroreport 5:
2057–2060.
41. Farooqui AA, Ong W-Y, Horrocks LA (2006) Inhibitors of Brain Phospholipase
A2 Activity: Their Neuropharmacological Effects and Therapeutic Importance
for the Treatment of Neurologic Disorders. Phamacol Rev 58: 591–620.
42. Sun GY, Xu J, Jensen MD, Simonyi A (2004) Phospholipase A2 in the central
nervous system: implications for neurodegenerative diseases. Journal of Lipid
Research 45: 205–213.
43. Sanchez-Mejia RO, Newman JW, Toh S, Yu G-Q, Zhou Y, et al. (2008)
Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of
Alzheimer’s disease. Nat Neurosci 11: 1311–1318.
44. Becker ML, Visser LE, Trienekens PH, Hofman A, van Schaik RHN, et al.
(2007) Cytochrome P450 2C9 *2 and *3 Polymorphisms and the Dose and
Effect of Sulfonylurea in Type II Diabetes Mellitus. Clin Pharmacol Ther 83:
288–292.
45. Magalhaes AC, Silva JA, Lee KS, Martins VR, Prado VF, et al. (2002)
Endocytic intermediates involved with the intracellular trafficking of a
fluorescent cellular prion protein. J Biol Chem 277: 33311–33318.
46. Prado MA, Alves-Silva J, Magalhaes AC, Prado VF, Linden R, et al. (2004) PrPc
on the road: trafficking of the cellular prion protein. JNeurochem 88: 769–781.
47. Madore N, Smith KL, Graham CH, Jen A, Brady K, et al. (1999) Functionally
different GPI proteins are organized in different domains on the neuronal
surface. EMBO J 18: 6917–6926.
48. Marijanovic Z, Caputo A, Campana V, Zurzolo C (2009) Identification of an
intracellular site of prion conversion. PLoS Pathog 5: e1000426.
49. Godsave SF, Wille H, Kujala P, Latawiec D, DeArmond SJ, et al. (2008) Cryo-
Immunogold Electron Microscopy for Prions: Toward Identification of a
Conversion Site. J Neurosci 28: 12489–12499.
50. White AR, Enever P, Tayebi M, Mushens R, Linehan J, et al. (2003)
Monoclonal antibodies inhibit prion replication and delay the development of
prion disease. Nature 422: 80–83.
51. Tzaban S, Friedlander G, Schonberger O, Horonchik L, Yedidia Y, et al. (2002)
Protease-Sensitive Scrapie Prion Protein in Aggregates of Heterogeneous Sizes.
Biochemistry 41: 12868–12875.
52. Beranger F, Mange A, Goud B, Lehmann S (2002) Stimulation of PrP(C)
retrograde transport toward the endoplasmic reticulum increases accumulation
of PrP(Sc) in prion-infected cells. J Biol Chem 277: 38972–38977.
53. Gilch S, Winklhofer KF, Groschup MH, Nunziante M, Lucassen R, et al. (2001)
Intracellular re-routing of prion protein prevents propagation of PrP(Sc) and
delays onset of prion disease. EMBO J 20: 3957–3966.
54. Lee KS, Linden R, Prado MAM, Brentani RR, Martins VR (2003) Towards
cellular receptors for prions. Reviews in Medical Virology 13: 399–408.
55. Bate C, Salmona M, Williams A (2004) The role of platelet activating factor in
prion and amyloid-b neurotoxicity. Neuroreport 15: 509–513.
56. Williams A, Van Dam AM, Ritchie D, Eikelenboom P, Fraser H (1997)
Immunocytochemical appearance of cytokines, prostaglandin E2 and lipocortin-
1 in the CNS during the incubation period of murine scrapie correlates with
progressive PrP accumulations. Brain Res 754: 171–180.
57. Williams AE, Van Dam AM, Man AHW, Berkenbosch F, Eikelenboom P, et al.
(1994) Cytokines, prostaglandins and lipocortin-1 are present in the brains of
scrapie-infected mice. Brain Res 654: 200–206.
58. Minghetti L, Cardone F, Greco A, Puopolo M, Levi G, et al. (2002) Increased
CSF levels of prostaglandin E(2) in variant Creutzfeldt-Jakob disease. Neurology
58: 127–129.
59. Minghetti L, Greco A, Cardone F, Puopolo M, Ladogana A, et al. (2000)
Increased brain synthesis of prostaglandin E2 and F2-isoprostane in human and
experimental transmissible spongiform encephalopathies. JNeuropatholExp-
Neurol 59: 866–871.
60. Gaudreault SB, Chabot C, Gratton JP, Poirier J (2004) The Caveolin
Scaffolding Domain Modifies 2-Amino-3-hydroxy-5-methyl-4-isoxazole Propio-
nate Receptor Binding Properties by Inhibiting Phospholipase A2 Activity. J Biol
Chem 279: 356–362.
61. Bate C, Williams A (2007) Squalestatin protects neurons and reduces the
activation of cytoplasmic phospholipase A2 by Ab1–42. Neuropharmacology 53:
222–231.
62. Mu ¨ller G, Schulz A, Wied S, Frick W (2005) Regulation of lipid raft proteins by
glimepiride- and insulin-induced glycosylphosphatidylinositol-specific phospho-
lipase C in rat adipocytes. Biochemical Pharmacology 69: 761–780.
63. Pietri M, Caprini A, Mouillet-Richard S, Pradines E, Ermonval M, et al. (2006)
Overstimulation of PrPC Signaling Pathways by Prion Peptide 106–126 Causes
Oxidative Injury of Bioaminergic Neuronal Cells. J Biol Chem 281:
28470–28479.
64. Vainio S, Heino S, Mansson JE, Fredman P, Kuismanen E, et al. (2002)
Dynamic association of human insulin receptor with lipid rafts in cells lacking
caveolae. EMBO Rep 3: 95–100.
65. Parpal S, Karlsson M, Thorn H, Stralfors P (2001) Cholesterol Depletion
Disrupts Caveolae and Insulin Receptor Signaling for Metabolic Control via
Insulin Receptor Substrate-1, but Not for Mitogen-activated Protein Kinase
Control. J Biol Chem 276: 9670–9678.
66. Mu ¨ller G, Hanekop N, Wied S, Frick W (2002) Cholesterol depletion blocks
redistribution of lipid raft components and insulin-mimetic signaling by
glimepiride and phosphoinositolglycans in rat adipocytes. MolMed 8: 120–136.
67. Nielsen D, Gyllberg H, Ostlund P, Bergman T, Bedecs K (2004) Increased levels
of insulin and insulin-like growth factor-1 hybrid receptors and decreased
glycosylation of the insulin receptor alpha- and beta-subunits in scrapie-infected
neuroblastoma N2a cells. Biochem J 380: 571–579.
68. Ostlund P, Lindegren H, Pettersson C, Bedecs K (2001) Up-regulation of
functionally impaired insulin-like growth factor-1 receptor in scrapie-infected
neuroblastoma cells. J Biol Chem 276: 36110–36115.
69. Srinivasappa J, Asher DM, Pomeroy KL, Murphy LJ, Wolff AV, et al. (1989)
Scrapie-induced diabetes mellitus in hamsters. Microbial Pathogenesis 7:
189–194.
70. Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM (2009) Cellular
prion protein mediates impairment of synaptic plasticity by amyloid-b oligomers.
Nature 457: 1128–1132.
Glimepiride and Prions
PLoS ONE | www.plosone.org 10 December 2009 | Volume 4 | Issue 12 | e8221